The regulatory ground beneath US food formulators has shifted, and the old playbook no longer holds. For decades, “previously approved” carried weight as a compliance shorthand. That assumption is now officially obsolete. With the FDA's landmark August 2026 proposed rule converting the voluntary GRAS notification program into a mandatory one, a patchwork of state-level warning laws gaining traction, and a synthetic dye injunction already disrupting interstate commerce, ingredient compliance has moved from a background consideration to a frontline business risk.
This post maps the current legal landscape in precise terms. You will learn what the mandatory GRAS rule actually requires, how Texas SB 25's 44-ingredient warning list interacts with the GRAS exemption, and what West Virginia's dye injunction means for formulators operating across state lines. You will also get a practical seven-step compliance checklist designed for the realities of 2027, plus a clear argument for why filtering by verified compliance status must come before ingredient selection, not after. If your formulation workflow still treats regulatory review as a final step, this analysis explains exactly why that approach has become a liability.
Why ‘Previously Approved' Is No Longer a Safe Assumption
For decades, self-affirmed GRAS status functioned as a regulatory safe harbor. Under the framework that evolved after 1958, manufacturers could make internal safety determinations and introduce substances into interstate commerce without FDA review, notification, or approval. Estimated at over 1,000 substances by 2011, this shadow inventory of self-affirmed ingredients operated entirely outside formal oversight.
That assumption is now obsolete.
On August 11, 2026, the FDA published proposed rule 2026-16296 in the Federal Register, converting the voluntary notification program into a mandatory requirement for the first time. Under proposed §§ 170.205(a) and 570.205(a), manufacturers must submit a GRAS notice before introducing any substance into interstate commerce under Section 201(s) of the FD&C Act. The self-affirmation pathway is eliminated.
The retroactivity provision is the sharpest break from prior practice. Already-marketed substances are explicitly covered, meaning ingredients that were self-affirmed years or decades ago carry the same new notification burden as anything entering commerce today. An ingredient cleared for scaled formulation under legacy assumptions now requires documented, current compliance validation to maintain that standing.
Federal reform does not stand alone. Texas SB 25 imposes mandatory warning labels on products containing any of 44 specified ingredients. West Virginia's synthetic dye injunction bans affected products from state distribution channels regardless of federal approval status. GRAS-reporting bills in New York, California, Pennsylvania, and New Jersey would independently render additives unlawful if manufacturers fail to report determinations, with New York's bill having already cleared the state senate on February 5, 2026. None of these state obligations are contingent on federal rule finalization.
The practical consequence is direct: ingredient compliance is now a multi-jurisdictional, time-sensitive obligation. An ingredient that passed your last review may already be non-compliant under one or more of these tracks. Periodic re-verification is no longer procedural due diligence; it is a core risk management function.
FDA's Mandatory GRAS Rule: What Changed and When
The proposed rule's mechanics establish a compliance clock with three distinct intervals formulators must track. Published August 11, 2026 in the Federal Register as document 2026-16296, the rule opened a 120-day public comment window that closed December 9, 2026. Once finalized, it takes effect 60 days after publication, at which point a compliance deadline begins for manufacturers to submit GRAS notices covering substances already in, or newly introduced into, interstate commerce. The scope extends to both 21 CFR Part 170 (human food) and Part 570 (animal food), and explicitly includes indirect food substances among them food-contact materials, a material expansion with real inventory implications.
FDA grounds its authority in FD&C Act sections 201, 402, 409, and 701. That statutory basis, however, is contested. The agency's own 2016 GRAS Final Rule preamble acknowledged it lacked express statutory authority to mandate notification, which is precisely the vulnerability a legal challenge would target. A 2021 S.D.N.Y. ruling reinforced this concern, signaling that regulatory changes of this magnitude belong to Congress rather than agency rulemaking. A challenge to the finalized rule is widely anticipated by regulatory counsel.
Congressional activity runs in parallel. H.R. 7291 proposes a separate HHS review board to reassess pre-2000 self-affirmed GRAS determinations, which represents a second federal vector that could force reformulations on an entirely different timeline, regardless of how litigation over the mandatory notification rule resolves.
For ingredient safety planning, the correct posture is to prepare as though the rule will be finalized on schedule. An injunction is possible but not guaranteed, and state-level obligations under Texas SB 25 and emerging reporting bills are independent of federal litigation outcomes entirely. Treating a potential legal challenge as a compliance extension is a high-risk assumption that conflates legal uncertainty with regulatory relief.
Streamlined vs. Full GRAS Submission: Which Pathway Applies to Your Ingredients
Understanding which pathway applies begins with a single threshold question: was the substance already in interstate commerce when the rule takes effect?
Subpart F, § 170.305 creates a streamlined option reserved exclusively for those legacy substances. It is available for one year from the effective date and carries a materially lighter documentation burden: formulators submit notification that the substance is in use and that a GRAS determination exists, with no obligation to include underlying safety data. For organizations managing established ingredient portfolios, that distinction is significant. Assembling a complete safety data package on dozens of legacy ingredients simultaneously is a resource-intensive undertaking; the streamlined pathway defers that burden for qualifying substances.
Any substance introduced into interstate commerce after the rule's effective date falls outside that window entirely and requires a full GRAS notice submission with complete safety data packages and comprehensive scientific support. Delay converts a lighter filing obligation into a heavier one: legacy substances whose formulators miss the one-year streamlined window face the same full-notice requirement as newly introduced substances.
Three Criteria Determine Your Pathway
Pathway eligibility turns on three factors:
- Date of market entry relative to the rule's effective date
- Existing GRAS documentation, whether self-affirmed or previously notified to FDA
- Substance category: human food, animal food, or indirect food (including food-contact materials under 21 CFR Parts 170 and 570)
Note that the streamlined option is also unavailable where FDA has previously issued an insufficient-basis letter or a not-GRAS determination for the specific use. Formulators should verify notification history through FDA's GRAS database before assuming streamlined eligibility.
Start the Triage Now
The practical implication for large portfolios is immediate: triage cannot wait for the final rule. Separating ingredients that qualify for streamlined submission from those requiring full notices allows compliance teams to sequence workloads, budget external resources, and file during the one-year window rather than scrambling against the outer deadline. Formulators who complete this inventory exercise before the rule is finalized will be positioned to file on day one of the effective date, capturing the full benefit of the streamlined pathway while others are still sorting their ingredient lists.
Texas SB 25: The 44-Ingredient Warning List and What the GRAS Exemption Actually Means
Separate from the federal notification timeline, a parallel state-level obligation is already live in Texas and runs on its own clock entirely.
Signed by Gov. Greg Abbott on June 22, 2025, Texas SB 25 takes effect January 1, 2027. Any food product sold in Texas containing one of 44 named ingredients must carry a mandatory warning: “WARNING: This product contains an ingredient that is not recommended for human consumption by the appropriate authority in Australia, Canada, the European Union, or the United Kingdom.” No risk assessment, no threshold quantity. If the ingredient is present, the warning is required.
The GRAS exemption warrants careful review. SB 25 includes exemption language referencing GRAS status; formulators should review the bill's precise exemption text with legal counsel to determine whether self-affirmed legacy determinations qualify. Given that FDA's proposed mandatory-notification rule explicitly targets already-marketed substances, any self-affirmed determination from years past deserves close scrutiny under both tracks. The two compliance obligations are converging on the same underlying requirement: current, documented GRAS status that can withstand regulatory scrutiny.
Multi-state formulators face a labeling bifurcation problem. A formulation compliant for national distribution may still trigger the Texas warning requirement, forcing either a Texas-specific label version or outright reformulation. Louisiana passed identical 44-ingredient warning legislation within weeks of SB 25, confirming this is a multi-state exposure, not a single-state edge case.
The 44-ingredient list concentrates heavily on synthetic additives, colorants, and preservatives, the same category targeted by West Virginia's dye injunction and the broader clean label ingredients shift. That convergence strengthens the reformulation case: ingredients already under state-level pressure federally and at the consumer level carry compounding risk.
Critically, SB 25 compliance is not a derivative of federal GRAS review. The timelines are not synchronized. Formulators should audit active formulations against the SB 25 list as a standalone step, independent of where those ingredients stand in the federal notification queue.
West Virginia's Synthetic Dye Injunction: Interstate Implications for Formulators
West Virginia's HB 2354 raises the stakes further: the law targets nine specific substances, including FD&C Blue No. 1, FD&C Red No. 40, FD&C Yellow No. 5, FD&C Yellow No. 6, and four additional certified color additives, along with butylated hydroxyanisole and propylparaben. A U.S. District Court granted a preliminary injunction in December 2025, temporarily halting the statewide retail ban on vagueness grounds, but the school nutrition program prohibition remains fully enforceable as of August 2025. West Virginia filed a notice of appeal in January 2026, and the Fourth Circuit is now reviewing the injunction.
For formulators, the injunction is not a clearance. It is a pause with an expiration date that no one can currently predict.
The deeper compliance problem is structural. A single SKU containing FD&C Red No. 40 is federally permitted today, yet the moment that product moves into West Virginia school distribution channels, it triggers an active legal obligation. Compliance status is no longer a fixed property of the ingredient; it is a function of the ingredient combined with the specific market and channel where the product is sold. National formulators managing hundreds of SKUs across broad distribution footprints cannot manually track that combination in a spreadsheet.
This mirrors the logic that produced the California Food Safety Act: a state identifies an ingredient category federal regulators have not yet restricted, passes enforceable law, and forces a market-wide response before federal action arrives. West Virginia follows that template precisely, and it will not be the last state to do so.
Federal pressure compounds state-level risk rather than replacing it. FDA revoked authorization for FD&C Red No. 3 in food and ingested drugs, effective January 2027, and launched a formal safety reassessment of butylated hydroxyanisole in February 2026. Both substances appear on West Virginia's list. Formulators still using either face simultaneous state injunction exposure and accelerating federal review, a compounded risk profile that makes continued use difficult to justify on any timeline.
Proactive reformulation toward natural colorants and verified clean label ingredients addresses the West Virginia exposure while building resilience against the broader state patchwork. Reformulating once, with compliance across the full distribution footprint as the design criterion, is materially less costly than reformulating reactively each time a new state acts.
The State-Level Patchwork: Tracking Bills in New York, California, Pennsylvania, and New Jersey
The pattern West Virginia's dye injunction illustrates is now repeating in northeastern and mid-Atlantic legislatures at an earlier stage, and formulators have a narrower window to get ahead of it.
New York is the most immediate risk. Senate Bill S1239 passed the state senate on February 5, 2026 and the assembly on April 21, 2026, and awaited Governor Hochul's signature as of late April 2026. If signed, the bill renders it unlawful to sell or use a GRAS substance in food unless a detailed safety report has been submitted to the New York Commissioner of Agriculture and Markets and published in a public database. Critically, this obligation applies independent of federal FDA notification status. Suppliers holding self-affirmed GRAS determinations without an FDA “no questions” letter face direct state reporting requirements under the bill's exemption structure. The GRAS provisions take effect 180 days after signature, meaning the compliance clock is near-term, not speculative.
California, Pennsylvania, and New Jersey have introduced comparable legislation, though none has cleared a full chamber as of 2026. That status should not reassure formulators. The California Food Safety Act followed precisely this trajectory: introduced as a niche measure, dismissed as unlikely to advance, then enacted with nationwide supply-chain consequences. Dismissing early-stage bills based on current momentum is the same miscalculation made with California's law.
The four bills do not align with each other or with federal requirements. Reporting deadlines, definitions of “GRAS determination,” and consequences for non-compliance vary by jurisdiction. A single federal GRAS notification filed under the mandatory rule does not automatically satisfy New York's state-database submission requirement, New Jersey's annual Department of Health reporting obligation, or the requirements taking shape in California and Pennsylvania. Each state track must be mapped and monitored separately.
For FDA regulations for food manufacturing compliance reviews, these bills represent a parallel obligation, not a derivative one. Federal compliance is the floor, not the ceiling.
Assign a named compliance owner to state-level bill tracking in each market state and build in a quarterly review cadence. Ad hoc monitoring has already proven insufficient given the pace of legislative activity through 2026; structured ownership is the operational minimum.
The Compliance Checklist: Seven Steps Before Ingredient Selection in 2027
With the federal and state landscape mapped, the following seven steps translate that complexity into a sequenced action plan every formulator should complete before selecting a new ingredient in 2027.
Step 1: Audit your existing ingredient inventory for GRAS status documentation. Identify every ingredient in active use that relies on a self-affirmed determination made before 2016. Flag each one for either streamlined submission under subpart F (§ 170.305) or full safety-data review. This inventory is the foundation for every subsequent step.
Step 2: Map the Texas SB 25 warning list against your formulations. Run each active SKU against the 44-ingredient list. Prioritize products in national distribution first, since Texas-bound SKUs are the immediate legal exposure, but a nationally distributed product carrying a warning-triggering ingredient will need resolution regardless of channel.
Step 3: Check synthetic colorant status against West Virginia's injunction and FDA's accelerated dye review schedule. Any certified color additive currently under state injunction or federal expedited review should be reclassified as elevated-risk. Treat continued approval as unconfirmed until verified, and begin reformulation scoping in parallel rather than waiting for a final regulatory outcome.
Step 4: Verify that clean label certifications are current and cover the relevant scope. Non-GMO Project, USDA Organic, and third-party clean label certifications support consumer-facing clean label positioning. Confirm that any certification scope covers the specific ingredients and applications at issue. An expired or scope-limited certification provides neither benefit.
Step 5: Confirm indirect food substance compliance for food-contact materials. The mandatory GRAS rule explicitly covers food-contact materials under 21 CFR Part 170. Packaging and processing aids must be included in the compliance audit; treating them as downstream procurement decisions rather than ingredient-stage compliance triggers is a common and costly oversight.
Step 6: Establish a streamlined-submission priority queue for the one-year window. Once the rule is finalized, the subpart F clock starts. Formulators who completed Step 1 before finalization can file immediately, avoiding the full data-submission burden and reducing exposure well before the outer deadline.
Step 7: Implement a compliance-first ingredient search workflow. New ingredient selection should begin with verified compliance status filtering, not end with it. Filtering by certification, GRAS documentation status, and regulatory risk profile before evaluating functional fit is the structural change this environment demands. Resources that speak like a technical resource, not a marketplace reflect the same discipline: compliance framing belongs at the front of the process, not appended after a commercial decision is already made. For a broader view of how ingredient intelligence supports this approach, the NXT Ingredients blog tracks regulatory developments as they affect ingredient selection in real time.
Why a Certification-First Ingredient Search Is Now a Risk Management Necessity
Implementing the seven-step checklist shifts your existing portfolio onto firmer ground. The harder structural change is what happens next: how new ingredients enter your development pipeline in the first place.
The legacy workflow carries a sequential risk that the current regulatory environment has made expensive. When an ingredient fails compliance review because it lacks a current GRAS notice, appears on Texas SB 25's 44-ingredient warning list, or falls under West Virginia's dye injunction, the technical investment in prototype development and application testing is stranded. A compliance-first workflow eliminates that risk by inverting the sequence.
Filter by verified GRAS status, applicable certifications, and clean label credentials before evaluating functional or commercial fit. Every ingredient that enters development carries a verified compliance baseline, so technical investment builds on regulatory viability rather than ahead of it.
NXT Ingredients' SmartSearch™ precision ingredient discovery makes this practical at scale. Formulators can filter simultaneously by certifications, application category, and function, which means the starting pool is already compliance-screened rather than requiring a post-selection audit pass.
Clean label certification earns its cost twice in this environment. It satisfies consumer-facing positioning requirements and simultaneously reduces documentation burden in regulatory proceedings. Certified ingredients typically carry well-maintained safety and sourcing records, which directly supports both mandatory GRAS notice preparation and state-level reporting obligations. One documentation investment serves multiple compliance tracks.
The competitive implication is direct. Across both supplier and brand tiers, the advantage now accrues to those who can demonstrate that an ingredient is verifiably compliant across the current federal and state landscape, not just that it performs. Documentation capability is a market differentiator. The 2027 FDA regulations for food manufacturing environment has made that true whether or not any individual formulator has yet reorganized their workflow around it.
Legal Uncertainty and the Case for Anticipatory Compliance
A compliance-first workflow addresses the current regulatory landscape effectively, but only if you actually build it now. The case for anticipatory action grows stronger, not weaker, when you account for the legal uncertainty surrounding the finalized GRAS rule.
A legal challenge to the rule is widely anticipated, and the temptation to wait is understandable: if a court enjoins the mandatory notification requirement, early investment in GRAS submission packages may seem wasted. That reasoning has a critical flaw. State-level requirements are legally independent of the federal rule. New York's GRAS-reporting obligation and Texas SB 25's 44-ingredient warning list advance on their own legislative and judicial timelines. A federal injunction does not pause them. Formulators who defer compliance work on the assumption that litigation will resolve the pressure are exposed to the state-level tracks regardless of what any federal court decides.
The risk compounds further when you factor in H.R. 7291. The proposed HHS review board for pre-2000 self-affirmed GRAS reassessments is a second federal vector, operating on a different congressional timeline than the mandatory notification rule. A formulation that survives an injunction challenge to the notification rule could still face forced reassessment under H.R. 7291, on a schedule entirely outside the notification framework.
Early movers carry a structural cost advantage here. If litigation produces a modified rule rather than a full injunction, firms with documentation already prepared face only incremental revision costs. Firms that waited face the full preparation burden on a compressed post-ruling timeline.
There is also a broader return on the investment. Ingredient safety documentation assembled for GRAS notification purposes does not sit idle in other contexts. It satisfies state-reporting obligations, supports product liability defense, and answers the retailer ingredient transparency requests that have become routine in national grocery procurement. The documentation cost is incurred once; the uses are multiple.
The risk calculus is asymmetric in the clearest possible way. Anticipatory compliance documentation carries a bounded, predictable cost. A reformulation forced by a state-level ban, or a failed self-affirmed GRAS defense in litigation, carries costs that are neither bounded nor predictable, and that ripple through supply chain relationships and commercialization timelines simultaneously. When one path has a ceiling and the other does not, waiting is not caution; it is a choice to accept unbounded downside risk.
Actionable Takeaways for Formulators Heading Into 2027
The asymmetric risk calculus established above translates directly into five priorities every formulator should act on before the end of 2026.
Treat the federal compliance deadline as an outer bound, not a planning target. The streamlined subpart F submission window closes at the one-year mark, well before that outer deadline. New York's GRAS-reporting bill, which already cleared the state senate on February 5, 2026, could impose an independent filing obligation before either federal window closes. File early or lose the streamlined option.
Complete the three-track audit (federal GRAS status, Texas SB 25 list exposure, colorant review) described above — each track runs on its own clock.
Adopt a compliance-first ingredient search workflow for all new formulation projects. Filter by verified GRAS status and clean label certifications before functional evaluation begins. NXT Ingredients supports exactly this sequence, letting formulators narrow by certification, application, and function simultaneously so every ingredient entering development carries a verified compliance baseline from day one.
Assign a named compliance owner to each of the four active state jurisdictions — New York, California, Pennsylvania, and New Jersey — and review each on a quarterly cadence. Legislative velocity in 2026 makes ad hoc monitoring a liability.
Use the current pre-finalization window to prepare streamlined submission packages for legacy self-affirmed GRAS ingredients. The rule is not yet final, but the documentation work is the same regardless of timing. Teams that complete it now can file within days of the effective date rather than scrambling against a running clock.
Conclusion
The regulatory landscape for US formulators has fundamentally shifted. Self-affirmed GRAS status is no longer sufficient protection, state-level ingredient bans are accelerating faster than federal timelines, and the cost of reactive compliance now far exceeds the cost of proactive preparation.
Three priorities define your path forward: complete a three-track federal, Texas, and colorant compliance audit before any formulation is finalized; adopt a certification-first ingredient search workflow so every new project starts from a verified baseline; and assign dedicated oversight to each active state jurisdiction before legislative windows close.
The formulators who reach 2027 in a strong position will be those who treated compliance as a design input, not an afterthought. Start your audit today, build your certified ingredient library now, and let every future formulation begin from a position of verified confidence rather than costly assumption.